Clinical Trial Update: ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis [Phase 4]

View source ↗

Summary

The Phase 4 trial of ACTHAR Gel for membranous lupus nephritis (class V) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Acthar Gel (repository corticotropin injection)

Snippet

Sponsor: Ohio State University | Conditions: SLE Glomerulonephritis Syndrome, WHO Class V | Phase 4 | Status: WITHDRAWN